Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses

Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
arcticnovartis

  • Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,2
  • 62% of patients treated with ianalumab plus eltrombopag achieved sustained platelet response at six months compared to 39% with placebo plus eltrombopag1,2
/by
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years

1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
arcticnovartis

  • Progression-free response stayed consistent across age, BMI, and menopausal status in MONALEESA pooled analysis1
  • KISQALI is only CDK4/6i to demonstrate statistically significant overall survival (OS) in MBC across all Phase III trials2-12
  • New NATALEE 5-year sub-analysis data reinforce sustained reduction in distant disease-free survival in broadest population of EBC patients13
/by
4/29/2026 : 2026 Annual General Meeting
/by
Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS

Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS
arcticnovartis

  • Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breaker
  • Scemblix data across clinical and real-world settings offer new evidence informing CML care amid evolving patient needs
  • 96-week pelabresib Phase III data represent longest follow-up of first-line myelofibrosis patients in randomized combination trial
/by
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets

Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by
Novartis announces plans to build flagship manufacturing hub in North Carolina

Novartis announces plans to build flagship manufacturing hub in North Carolina
arcticnovartis

  • Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030
  • Enables manufacturing of medicines across company’s main therapeutic areas in one geographic location
/by
1/13/2026 : J.P. Morgan Healthcare Conference

View the live Webcast

/by
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials

Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
arcticnovartis

  • NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit1 
  • Data showed consistent improvements across secondary outcome measures, and a favorable safety profile1 
  • Novartis plans to submit to health authorities globally in early 2026
  • If approved, ianalumab could become first targeted treatment for this heterogeneous, systemic autoimmune disease
/by
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline

New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
arcticnovartis

  • Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolio
  • C3 glomerulopathy (C3G) studies add to body of evidence of Fabhalta long-term safety and efficacy profile in native and post-transplant disease recurrence patients
  • V-INCEPTION analyses highlight Leqvio adherence and goal attainment data when initiated early in post-acute coronary syndrome patients
/by